Found: 142
Select item for more details and to access through your institution.
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 5, p. 1938, doi. 10.1007/s12325-024-02822-z
- By:
- Publication type:
- Article
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 3, p. 321, doi. 10.1007/s11523-024-01054-z
- By:
- Publication type:
- Article
Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 1, p. 48, doi. 10.1002/ajh.27137
- By:
- Publication type:
- Article
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 12, p. 2744, doi. 10.1111/cts.13669
- By:
- Publication type:
- Article
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Long‐term follow‐up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T‐cells in follicular lymphoma patients treated by rituximab‐maintenance regimen.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 3, p. 686, doi. 10.1111/bjh.18881
- By:
- Publication type:
- Article
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
- Published in:
- Annals of Hematology, 2023, v. 102, n. 7, p. 1773, doi. 10.1007/s00277-023-05196-4
- By:
- Publication type:
- Article
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L‐asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T‐cell lymphoma: A French retrospective study.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 4, p. 673, doi. 10.1111/bjh.18689
- By:
- Publication type:
- Article
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 2, p. 256, doi. 10.1111/bjh.18642
- By:
- Publication type:
- Article
Long‐term outcomes of patients with limited‐stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 4, p. 524, doi. 10.1111/bjh.18590
- By:
- Publication type:
- Article
Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe.
- Published in:
- EJHaem, 2023, v. 4, n. 1, p. 45, doi. 10.1002/jha2.593
- By:
- Publication type:
- Article
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2--Technical).
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 2, p. 239, doi. 10.2967/jnumed.122.264124
- By:
- Publication type:
- Article
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1--Clinical).
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 1, p. 102, doi. 10.2967/jnumed.122.264106
- By:
- Publication type:
- Article
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 11, p. e1009, doi. 10.1016/j.clml.2022.07.015
- By:
- Publication type:
- Article
APPLICATION OF THE LUGANO CLASSIFICATION FOR INITIAL EVALUATION, STAGING, AND RESPONSE ASSESSMENT OF HODGKIN AND NON-HODGKIN LYMPHOMA: THE PROLOG CONSENSUS INITIATIVE (PART 1- CLINICAL).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264106
- By:
- Publication type:
- Article
APPLICATION OF THE LUGANO CLASSIFICATION FOR INITIAL EVALUATION, STAGING, AND RESPONSE ASSESSMENT OF HODGKIN AND NON-HODGKIN LYMPHOMA: THE PROLOG CONSENSUS INITIATIVE (PART 1- CLINICAL).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264106
- By:
- Publication type:
- Article
APPLICATION OF THE LUGANO CLASSIFICATION FOR INITIAL EVALUATION, STAGING, AND RESPONSE ASSESSMENT OF HODGKIN AND NON-HODGKIN LYMPHOMA: THE PROLOG CONSENSUS INITIATIVE (PART 2- TECHNICAL).
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264124
- By:
- Publication type:
- Article
The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 3, p. 370, doi. 10.1002/hon.2978
- By:
- Publication type:
- Article
Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.
- Published in:
- Cancers, 2022, v. 14, n. 7, p. 1761, doi. 10.3390/cancers14071761
- By:
- Publication type:
- Article
Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 3, p. 519, doi. 10.1002/cncr.33938
- By:
- Publication type:
- Article
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 1, p. 61, doi. 10.1002/cam4.4422
- By:
- Publication type:
- Article
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 10, p. 1295, doi. 10.1002/ajh.26301
- By:
- Publication type:
- Article
Poster: ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S239, doi. 10.1016/S2152-2650(21)01499-3
- By:
- Publication type:
- Article
ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S392, doi. 10.1016/S2152-2650(21)01891-7
- By:
- Publication type:
- Article
Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 8, p. 1, doi. 10.1038/s41408-021-00539-8
- By:
- Publication type:
- Article
Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 2, p. 382, doi. 10.1111/bjh.17550
- By:
- Publication type:
- Article
Real‐life targeted next‐generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 6, p. 1110, doi. 10.1111/bjh.17395
- By:
- Publication type:
- Article
Optimizing CAR T cell therapy in lymphoma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. 599, doi. 10.1002/ajh.26149
- By:
- Publication type:
- Article
Diffuse large B-cell lymphoma: new targets and novel therapies.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 4, p. 1, doi. 10.1038/s41408-021-00456-w
- By:
- Publication type:
- Article
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Highlights in Relapsed/Refractory Follicular Lymphoma From the 62nd American Society of Hematology Annual Meeting and Exposition: Commentary.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, p. 13
- By:
- Publication type:
- Article
The use of tafasitamab in diffuse large B-cell lymphoma.
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/20406207211027458
- By:
- Publication type:
- Article
The role of tazemetostat in relapsed/refractory follicular lymphoma.
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/20406207211015882
- By:
- Publication type:
- Article
Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effects.
- Published in:
- PLoS ONE, 2020, v. 15, n. 12, p. 1, doi. 10.1371/journal.pone.0243309
- By:
- Publication type:
- Article
Drug cost savings in phase III hematological oncology clinical trials in a university hospital.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1472, doi. 10.1007/s10637-020-00916-3
- By:
- Publication type:
- Article
Current and Novel Approaches in DLBCL.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 9, p. 379
- By:
- Publication type:
- Article
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 5, p. 510, doi. 10.1002/ajh.25757
- By:
- Publication type:
- Article
Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 5, p. 1, doi. 10.1038/s41408-020-0322-5
- By:
- Publication type:
- Article
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B‐cell lymphoma, a clinico‐pathological series of 25 cases.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 2, p. 244, doi. 10.1111/bjh.16331
- By:
- Publication type:
- Article
Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant.
- Published in:
- Cancers, 2020, v. 12, n. 4, p. 901, doi. 10.3390/cancers12040901
- By:
- Publication type:
- Article
Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.
- Published in:
- International Journal of Environmental Research & Public Health, 2020, v. 17, n. 5, p. 1783, doi. 10.3390/ijerph17051783
- By:
- Publication type:
- Article
Genetically Determined Height and Risk of Non-hodgkin Lymphoma.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2019.01539
- By:
- Publication type:
- Article
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B‐cell non‐Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 2, p. 240, doi. 10.1111/bjh.16255
- By:
- Publication type:
- Article
Lymphome folliculaire : vingt années de progrès, et encore de multiples défis !
- Published in:
- 2019
- By:
- Publication type:
- Editorial